Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nonacog beta pegol in Chinese patients with haemophilia B
NCT05365217Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- May 2022
- Primary completion
- Apr 2024
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of nonacog beta pegol in Hemophilia B (HB) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Haemostatic Effect of Nonacog Beta Pegol When Used for Treatment of Bleeding Episodes at 50 weeks. Started May 2022; status: completed.
02
Drugs
nonacog beta pegol
03
Conditions
Hemophilia B (HB)
Beyond the preview
Go deeper on NCT05365217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05365217.